47 completed, 12 terminated, 4 recruiting, 4 unknown. 72 Phase 1, 28 Phase 2.
Follow Mitoxantrone: new trials by email Literature Review of Mitoxantrone trials Research Report on Mitoxantrone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1 - Relapsed Adult AML, Refractory AML | Phase 1 | Withdrawn | Medical College of Wisconsin | 2024-08-31 | 2024-08-13 | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Ayman H Qasrawi | 2023-03-01 | 2023-04-25 | |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-11-06 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor - Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia | Phase 1 | Terminated | University of Washington | 13 | 2020-05-08 | 2023-12-28 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Prexasertib, Mitoxantrone, Etoposide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Dana-Farber Cancer Institute | 2 | 2019-01-18 | 2019-06-12 |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Cladribine, Cytarabine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 66 | 2018-09-14 | 2023-08-30 |
| BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) BrentuximabVedotin (BV) - Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 41 | 2018-08-08 | 2024-02-26 |
| Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia Lintuzumab-Ac-225, Cladribine, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Completed | Medical College of Wisconsin | 26 | 2018-05-22 | 2024-10-08 |
| A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia Alvocidib, Cytarabine, Mitoxantrone - Acute Myeloid Leukemia | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 10 | 2018-05-15 | 2022-04-12 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University of Washington | 84 | 2016-12-01 | 2023-07-05 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Cladribine, Cytarabine, Decitabine - Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 28 | 2016-11-17 | 2020-03-17 |
| Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia Hydroxychloroquine, Mitoxantrone, Etoposide - Leukemia, Acute Myelogenous | Phase 1 | Terminated | Alison Sehgal, MD, MS | 1 | 2016-08-18 | 2018-02-23 |
| Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Crenolanib, Mitoxantrone, Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Completed | Arog Pharmaceuticals, Inc. | 16 | 2016-02-01 | 2023-12-20 |
| Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I ITMHA, Dexamethasone, Mitoxantrone - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 50 | 2016-01-29 | 2026-06-24 |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation AG-120, AG-221, cytarabine - Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML | Phase 1 | Active not recruiting | Institut de Recherches Internationales Servier | 153 | 2015-12-31 | 2026-05-22 |
| Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Cytarabine, Mitoxantrone Hydrochloride, Selinexor - Acute Myeloid Leukemia | Phase 1 | Completed | University of Chicago | 25 | 2015-10-07 | 2020-04-08 |
Showing 20 of 72. Sign in to see all of them.
Leukemia, Myeloid, Acute (46) · Leukemia (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Congenital Abnormalities (13) · Leukemia, Monocytic, Acute (10) · Leukemia, Erythroblastic, Acute (8) · Leukemia, Megakaryoblastic, Acute (8) · Leukemia, Myelomonocytic, Acute (8) · Myelodysplastic Syndromes (6) · Recurrence (6) · Leukemia, Biphenotypic, Acute (5) · Prostatic Neoplasms (5) · Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Leukemia, Basophilic, Acute (2)
Fred Hutchinson Cancer Center (9) · National Cancer Institute (NCI) (8) · University of Washington (3) · Washington University School of Medicine (3) · Amgen (2) · Arog Pharmaceuticals, Inc. (2) · Case Comprehensive Cancer Center (2) · Massachusetts General Hospital (2) · Medical College of Wisconsin (2) · Memorial Sloan Kettering Cancer Center (2) · University of Chicago (2) · Wake Forest University Health Sciences (2) · Abramson Cancer Center at Penn Medicine (1) · Alice Mims (1) · Alison Sehgal, MD, MS (1)
United States (63) · Canada (7) · Australia (5) · France (3) · Italy (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Czechia (1)
Roland Walter (4) · Anjali Advani (2) · Anna Halpern (2) · Judith Karp (2) · Renier Brentjens, MD, PhD (2) · Alice Mims, MD (1) · Alison Sehgal, MD (1) · Alison Walker (1) · Alison Walker, MD (1) · Amir Fathi, MD (1) · Andrea Harzstark (1) · Andrew D. Zelenetz, MD, PhD (1) · Andrew Kent, MD, PhD (1) · Ann Mohrbacher (1)
PMID 18299450, PMID 18467731, PMID 19349545, PMID 19638218, PMID 20071660, PMID 20209646, PMID 21239698, PMID 22308295, PMID 23233571, PMID 24048789, PMID 25034977, PMID 26376115, PMID 26784138, PMID 29304833, PMID 31860140, PMID 31969338, PMID 32074275, PMID 32077361, PMID 33394722, PMID 34543383, PMID 35166065, PMID 35354808, PMID 35689544, PMID 36215217, PMID 37339483, PMID 37665178, PMID 38507688, PMID 40535475, PMID 40641817, PMID 41671463, PMID 41692013, PMID 42234929
P30CA015704 (5), P30CA012197 (2), U01CA070095 (2), 2008 (1), 2009 (1), 2014 (1), 2015 (1), N01CM00032 (1), N01CM62202 (1), N01CM62203 (1), P30CA014599 (1), P30CA016058 (1), P30CA016672 (1), P30CA023108 (1), P30CA043703 (1)